YieldMax AMZN Option Income Strategy ETF vs Cronos Group Inc — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $11.42, while Cronos Group Inc trades at $3.08 (market cap $1.11B). The key difference: Cronos Group Inc is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMZY | CRON | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $15.75 | $3.27 |
52-Week Low | $9.98 | $2.30 |
Market Cap | — | $1.11B |
Enterprise Value | — | $310.67M |
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $11.54, up 0.87% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The stock faces critical support at $11 and resistance at $12. Recent news highlights consistent weekly dividend distributions, though analyst reports express concerns over potential net asset value erosion despite the high yield strategy.
The outlook is mixed; the high-yield dividend strategy attracts income investors, but fundamental risks include underperformance versus Amazon and sustainability of payouts. Key risks involve amplified downside exposure and competitive pressures, warranting cautious evaluation for long-term growth-oriented investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →